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http://dx.doi.org/10.1016/j.kjms.201Abstract We analyzed the ratio of serum total testosterone (sTT) to prostate-specific antigen
(PSA) as a predictor of prostate cancer risk. One-hundred-four consecutive men with a normal
digital rectal examination and a serum PSA level of 2.5e10 ng/ml underwent transrectal
ultrasonography-guided biopsy using a 10-core scheme. The sTT level was determined before
the procedure using a chemiluminescent assay, and the ratio of sTT to PSA (sTT/PSA) was
calculated after transforming sTT measurements from ng/dL to ng/mL. The overall cancer
detection rate was 17.3%. The median sTT level was 332 ng/dl in men with cancer and
413 ng/dL in those without (p Z 0.032). The median sTT/PSA ratio in these groups was 0.55
and 0.74, respectively (p Z 0.035). The receiver operator characteristic (ROC) method was
used to evaluate the properties of the sTT/PSA ratio, with testosterone and PSA as predictors
of prostate cancer risk. The accuracy of the sTT/PSA ratio in prostate cancer diagnosis, repre-
sented by the area under the curve (AUC), was 0.739 (95% CI 0.640e0.823, p < 0.05).
Optimizing the sensitivity and specificity of the sTT/PSA ratio using the ROC provided a cutoff
point of 0.60, which corresponded to 82% sensitivity and 62% specificity. When the patients
were divided into normal- and low-sTT level groups according to testosterone value
(300 ng/dl), the probability of detecting prostate cancer was 3.3-fold higher in hypogonadal
men as compared with eugonadal men. These results support the use of the sTT-to-PSA ratio
for predicting the risk of prostate cancer and increasing the specificity of PSA measurement.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.llesi, _Ilkkent Camlık Sitesi, B
.com (C. Gurbuz).
vier Taiwan LLC. All rights reserv
2.01.003Introduction
The introduction of serum prostate-specific antigen (PSA)
screening has made the early detection of prostate cancer
possible. Nonetheless, serum PSA is not a perfect disease
marker, most notably because of its low specificity. PSA
elevations can be caused by both prostate cancer and
nonmalignant diseases, such as benign prostatic hyperplasiaed.
650 C. Gurbuz et al.or chronic prostatitis [1]. Unnecessary biopsies are still an
important clinical issue.
The potential clinical applications of serum total
testosterone (sTT) determination in patient screening,
diagnosis and the management of prostate cancer have
been evaluated in the literature [2]. Currently, the asso-
ciation of serum testosterone with prostate cancer is
incompletely understood. Studies comparing circulating
male sex hormone levels between subjects with and
without prostate cancer have produced widely varying
results [3,4]. The usefulness of using the sTT/PSA ratio as
a predictor of prostate cancer risk was recently suggested
by Karamanolakis et al. [5]. Rhoden et al. [6] confirmed its
usefulness in hypogonadal men with low levels of serum
PSA. Morote et al., however, failed to confirm that it is
a useful tool to increase the specificity of PSA in eugonadal
or hypogonadal men [7].
The main objective of the present study was to analyze
the relationship between sTT and PSA levels and the risk of
prostate cancer in a consecutive cohort of eugonodal and
hypogonadal men with normal DRE and a serum PSA level of
2.5e10 ng/ml.Methods
The study was executed in accordance with the Declaration
of Helsinki, International Conference on Harmonisation
Guidelines for Good Clinical Practice, and applicable
regulatory guidelines. Between October 2008 and March
2010, 104 patients were included in this study. All partici-
pants provided their written informed consent. The mean
patient age was 63.7 years (42e73 years). Patients with
elevated PSA levels (2.5e10 ng/ml) who underwent
a transrectal ultrasound prostate biopsy were included in
the study. Exclusion criteria included the following:
 men on medications known to lower PSA, such as
finasteride or dutasteride, or any antibiotic treatment;
 patients receiving anticoagulant therapy;
 patients who had an indwelling Foley catheter, a symp-
tomaticorasymptomaticurinary tract infection,bleeding
disorders, acute prostatitis before prostate biopsy,
a previous prostatic biopsy or prostate surgery; and
 total length of tissue obtained via biopsy of <10 cm.
Total serum PSA levels, with a reference range of 0.003e
100.0 ng/mL, were measured by electrochemiluminescence
immunoassay (Modular Analytics E170, Roche Diagnostics,
Switzerland; interassay CV <3.2%). The sTT levels, with
a reference range of 2.5e1500.0 ng/dl, were determinedTable 1 Clinical and laboratory features in men with and witho
Benign biopsy (n Z 86)
Age (yr) 63.45  6.57
PSA (ng/ml) 6.27  1.86
Volume (cm3) 51.97  24.46
Total testosterone (ng/ml) 4.13  1.52
Testosterone/PSA 0.74  0.38
Bold values represent values with p < 0.05.using a solid-phase, competitive chemiluminescent enzyme
immunoassay, using the Immulite 2500 automated analyzer
device (DPC Inc., Los Angeles, CA, USA; interassay CV
<4.1%.
Blood samples were obtained between 08:00 and 10:00
hours and processed immediately. Men with sTT <300 ng/dl
were considered hypogonadal [6]. The sTT to PSA ratio was
calculated after transforming sTT levels into ng/mL, the
units in which PSA is normally expressed.
The biopsy procedure was performed on patients in the
left lateral decubitus position using a Toshiba Fabio scanner
with an attached 7.5 MHz biplanar probe (Toshiba, Tokyo,
Japan). The 10 core prostate biopsies (traditional sextant
biopsy cores and four laterally-placed biopsies in the right
and left apex and mid-portion of the prostate gland) were
obtained with a spring-loaded biopsy gun (C. R. Bard, Inc.,
Covington, Georgia, USA) and an 18-gauge Tru-cut biopsy
needle (UK Medical, Sheffield, UK). The core-sampling notch
was approximately 17 mm long and 12 mm in diameter.
Statistical evaluation
Data are presented as mean standard deviation (SD). The
differences between group variables were evaluated by
unpaired t-test, and the Chi-square test was used to
evaluate qualitative variables. A receiver operator char-
acteristic (ROC) curve analysis was used to evaluate the
properties of the sTT/PSA ratio as a predictor of prostate
cancer risk and identify an optimal cutoff point for the test
in this particular study population. Further analysis of the
sTT/PSA ratio was performed based on cutoff values ob-
tained by an ROC curve method. Statistical significance was
considered at p < 0.05.
Results
There were 86 men (82.7%) with benign prostate biopsies
and 18 (17.3%) with prostate cancer. There were no
significant differences between these groups with regard to
age, prostate volume and PSA level. The total testosterone
values and sTT/PSA ratio, however, were found to be
statistically lower in the prostate cancer group (Table 1).
The characteristics of men with prostate cancer are pre-
sented in Table 2. When the patients are divided to normal-
and low-sTT level groups according to testosterone value
(3 ng/ml), the probability of detecting prostate cancer
was significantly higher (age-adjusted odds ratio [OR] 3.3;
95% confidence interval [CI]: 1.15e9.43) in hypogonadal
men as compared with eugonadal men (25.9% vs. 14.3%,
p Z 0.044).ut prostate cancer.
Prostate cancer (n Z 18) p
64.06  5.66 0.719
6.75  2.00 0.333
49.17  19.87 0.385
3.32  1.00 0.032
0.55  0.28 0.035
Table 2 Characteristics of men with prostate cancer.
Patient number Age (years) PV (cm3) PSA (ng/ml) Testosterone (ng/ml) sTT/PSA Gleason grade
1 59 41 7.7 1.93 0.205 3 þ 3
2 71 30 6.1 2.05 0.336 3 þ 3
3 66 30 9.0 2.05 0.227 5 þ 5
4 62 36 4.2 2.42 0.576 3 þ 3
5 53 21 5.0 2.43 0.486 3 þ 3
6 65 30 7.0 2.49 0.355 4 þ 4
7 66 75 6.9 2.92 0.423 3 þ 3
8 69 40 5.3 3.02 0.569 4 þ 4
9 50 43 7.6 3.17 0.417 3 þ 3
10 67 48 5.1 3.44 0.674 4 þ 4
11 70 40 8.6 3.61 0.419 3 þ 3
12 68 24 2.7 3.67 0.136 3 þ 3
13 61 60 6.3 3.83 0.607 3 þ 3
14 68 35 8.0 3.94 0.492 4 þ 4
15 65 38 9.9 4.08 0.412 3 þ 3
16 67 65 9.0 4.54 0.504 3 þ 3
17 60 26 4.4 5.00 0.111 3 þ 3
18 66 23 8.7 5.40 0.627 3 þ 4
PSA e prostate-specific antigen; PV e prostate volume; sTT e serum total testosterone.
Bold numbers indicates abnormal values.
Figure 1. A receiver operator characteristic (ROC) curve for
sTT/PSA ratio, testosterone and PSA in the prediction of
prostate cancer.
Testosterone to PSA ratio 651The frequency of high-grade cancer (Gleason score >6)
was reported as 28% (2/7) and 36% (4/11) in hyopogonadal
and eugonodal patients, respectively (p Z 0.648).
The ROC curve method was used to evaluate the prop-
erties of the sTT/PSA ratio, with testosterone and PSA
levels as predictors of prostate cancer risk. It was used to
identify an optimal cutoff point for the sTT/PSA ratio in this
particular study population. The accuracy of the sTT/PSA
ratio in the presence prostate cancer diagnosis, repre-
sented by the area under the curve (AUC), was 0.739 (95%
CI: 0.640e0,823, p <0.05). Optimizing the sensitivity and
specificity of the sTT/PSA ratio using the ROC provided
a cutoff point of 0.60, which corresponded to 82% sensi-
tivity and 62% specificity (Fig. 1). Four of the 15 men with
high-grade cancer (Gleason score >6) had sTT/PSA ratio of
values <0.60, which is the threshold value proposed by our
study.
Discussion
Although the pathological and therapeutic significance of
the androgen axis is known, there is currently no widely
recognized application of serum testosterone determina-
tion in determining prostate cancer risk using PSA level.
There is substantial controversy in the literature regarding
the association between testosterone levels and prostate
cancer risk.
The usefulness of the sTT/PSA ratio as a predictor of
prostate cancer risk was suggested by Karamanolakis et al.
[5]. These authors analyzed a group of 97 patients with
a serum PSA level of 3e10 ng/mL who underwent a sextant
transrectal ultrasound-guided biopsy. We observed signifi-
cantly lower sTT levels and significantly lower sTT/PSA
ratios in patients with prostate cancer than in those who
provided biopsies that were free of any sign of cancer.
Using 0.95 as the threshold level for sTT/PSA, thesensitivity was 96.5% and the specificity was 81% for the
diagnosis of prostate cancer. Rhoden et al. [6] analyzed the
usefulness of the sTT/PSA ratio in 184 consecutive men with
symptomatic hypogonadism and a PSA level of 4.0 ng/ml
that underwent sextant biopsy. The sTT/PSA ratio was
found to be inversely related to prostate cancer risk. A
sTT/PSA ratio of <1.8 was diagnostic for prostate cancer,
while values below this threshold were associated with an
odds ratio of 3.0 for prostate cancer. These two studies
[5,6] support the determination of a testosterone-to-PSA
ratio as an adjunctive diagnostic test in patients with
mild PSA elevations or patients with hypogonadism and
borderline PSA values, albeit with different thresholds for
these two groups. Morote et al. [7], however, failed to
reproduce these results in patients with PSA levels of
652 C. Gurbuz et al.4.1e20 ng/ml. Their study did not support the use of
a sTT/PSA ratio as a predictor of prostate cancer risk in
clinical practice. Furthermore, Morote et al. also failed to
detect any utility for this ratio in hypogonadal men with
PSA levels of 4.1e20 ng/ml.
There have been many attempts to characterize the
influence of the prostate on serum hormone levels. Some
studies suggest that high testosterone levels are associated
with an increased risk of prostate cancer [8,9]. Yano et al.
[10] reported that the positive rate of prostate biopsy in
patients with a sTT level >5.5 ng/ml was significantly
higher than in patients with sTT <5.5 ng/ml. Our findings
were inconsistent with these results. The mechanisms that
lead to the endocrine changes observed in men with pros-
tate cancer are not clear. Imamoto et al. recently reviewed
10 modest-sized prospective studies to determine the role
of testosterone in the pathogenesis of prostate cancer.
Results from these studies have been inconclusive [11].
Within the diagnostic ‘‘gray zone’’ (PSA of 2.5e10 ng/
ml), the risk of prostate cancer detectable by modern
biopsy protocols is around 25%, making unnecessary biop-
sies an important clinical issue [12]. The overall rate of
prostate cancer detection in the first round of biopsy was
approximately 20% in the present study. The biopsy scheme
was modified by increasing the minimum number of cores
from eight to 10. A 12-core biopsy was sometimes recom-
mended in the second-round biopsy. Previous studies that
supported the use of the sTT/PSA ratio were criticized
because sextant biopsies were used and a significant
number of prostate cancers may have been missed. The
strengths of this present study include its evaluation of 10
biopsy cores per patient.
It is difficult to compare the present study with other
studies because PSA and sTT levels had different distribu-
tions. The diagnosis of hypogonadism is based on a sTT
level <3 ng/ml in the present study. The risk of prostate
cancer detection increased 3.3-fold for hypogonadal men
compared with eugonodal men in the current study. Hoff-
man et al. [13] reported that in patients with low compared
to normal free testosterone, there was an increased mean
percentage of biopsies that showed cancer (43% vs. 22%,
p Z 0.013). However, Rhoden [6] did not show any rela-
tionship between total testosterone level and an increased
risk of prostate cancer.
The association between low serum testosterone and
high-grade prostate cancer is not clear in the literature
[14,15]. Several hypotheses suggest why aggressive tumors
may be more common in men with low testosterone. The
first hypothesis states that prostate cancer inhibits
androgens through negative feedback mediated by inhibin,
PSA and dihydrotestosterone [16]. According to another
hypothesis, the hormonal milieu might be varied enough to
disrupt the normal growth and maintenance of prostatic
tissue, while compensatory hyperplasia that results when
the prostate atrophies might lead to cell mutation and the
consequent selection of androgen-independent, aggressive
prostate cells [17]. Previous studies have indicated that
a lower sTT level might represent a marker for more
aggressive disease [18,19]. In the present study, we did not
observe any relationship between high-grade tumors and
low testosterone levels. This variation may be due to the
relatively small patient cohort.Sex steroid hormones are thought to contribute to the
growth, differentiation, and progression of prostate cancer.
We only measured plasma concentrations of total testos-
terone. Total testosterone may not represent the true level
of the biological male sex hormone. The possible associa-
tions between free testosterone, dihydrotestosterone,
androstanediol, estradiol, and sex hormone-binding glob-
ulin and prostate cancer are not clear [19]. We did not
focus on sex steroid hormone indices other than total
testosterone.
There are some limitations of this study that we need to
address, including the limited number of patients involved
and the fact that not all of the biopsies were performed by
a single person. We did not assess the role of the sTT/PSA
ratio in making a decision regarding the second round of
biopsies after a negative first biopsy round. There is no
consensus on the cutoff values to be used for the sTT/PSA
ratio. In the present study, a sTT/PSA ratio cutoff point
of 0.6 was used, whereas this value was 0.95 for
Karamanolakis et al. [5] and 1.8 for Rhoden et al. [6]. The
value that is most appropriate can only be determined
through large clinical trials. Measuring testosterone and
calculating the sTT/PSA ratio may help us to identify men
at increased risk of prostate cancer and to improve diag-
nostic accuracy in men with otherwise borderline PSA.
There are inconsistent results in the literature as to
whether testosterone measurement is useful in prostate
cancer screening strategies. The present study suggests
that the sTT/PSA ratio might be considered a predictor of
the risk of prostate cancer. Within the diagnostic ‘‘gray
zone ’’ (PSA of 2.5e10 ng/ml), the rate of prostate cancer
detection was found to be higher in hypogonadal compared
to eugonadal men. Our study showed that the sTT/PSA ratio
seems to be useful in detecting prostate cancer risk.
Despite this, further evaluation of serum testosterone to
improve the specificity of PSA testing is warranted.
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